Life Science combination products
Fighting the war on diseases and cancers through developing combination products to challenge unmet medical diagnosis for patients
This device combination is one of a novel development of a "liquid stent";
Targeting mechanism for:
Atrial Myxoma and atrial stenosis leading to coronary arterial disease.
A unique approach to hemoglobin, protein and synthetic cell modification; this combination device is targeting a two pronged approach in the following:
Pantothenate Kinase-Associated Neurodegeneration (PKAN) to Amyotrophic Lateral Sclerosis (ALS)
Paroxysmal Nocturnal Hemoglobinuria (PNH) to Lewy Body Dementia
Pediatric combination device infused with nanotech synthetic cells targeting pediatric patients that suffer from Diffuse Intrinsic Pontine Glioma (DIPG).
Our initial development and furthest one along in our product development pipeline. Currently in phase II clinical trials. This device is geared toward having your musculoskeletal system regenerate bone, tissue, ligament and muscle in the hip. Targeting arthrodesis & osteopenia to bone marrow disease
To find out more about our combination products or to partner with us in the development stages, contact us below.